Company profile
Cardiff Oncology, Inc.
NASDAQ: CRDF · Healthcare · Biotechnology
#924 of 1,422 Healthcare companies by revenue30th-percentile growth
EA Score
52DFH 32DQ 79GM 56SS 61
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ operating margin, net margin
Methodology →Revenue TTM
$525.0k
Rev growth YoY (TTM)
-10.7%
Net income (FY)
-$45.9M
Employees
31
as of 2026-08-18
Market cap
$70.3M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$593.0k$593.0k2025
Net income-$45.9M-$45.9M2025
Operating income-$49.0M-$49.0M2025
Total assets$61.9M$61.9M2025
Liabilities$16.5M$16.5M2025
Equity$45.4M$45.4M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2020
By product
Royalty100%
By geography
Not disclosed.
The read
What is Cardiff Oncology, Inc.’s revenue?
Cardiff Oncology, Inc. booked $593.0k in FY2025 revenue, contracting 13% year over year — slower than 70% of Healthcare companies we track, at a -7732.0% net margin.
Peers · Healthcare
Theralink Technologies, Inc.——Vaccinex, Inc.——CBD of Denver, Inc.35DPMGC Holdings Inc.29DGrapefruit USA, Inc.——Theralase Technologies Inc.37DNeighbors
San Diego →Key facts
CEOMani Mohindru
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: CRDF
Employees31
IPO date2004-07-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.